Phase 1 Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older at the time of signing the consent form
- People who are able and willing to sign a consent form agreeing to take part
- People who have been clinically diagnosed with ACM (arrhythmogenic cardiomyopathy) based on a specific set of recognised diagnostic criteria from 2010
- People who have a confirmed harmful or likely harmful gene change (mutation) in a gene called PKP2
- People who have had an ICD (a small device implanted in the chest to help control dangerous heart rhythms) for at least 6 months before joining the trial
- People whose heart monitoring shows at least 500 extra or irregular heartbeats (PVCs) within a 24-hour period
- People whose left side of the heart is pumping at a normal or near-normal level (at least 50%), as measured by an ultrasound or special heart scan
Who may not be able to join:
- People whose blood tests show a high level of antibodies against a specific component used in the treatment (anti-AAVrh.74 antibody levels above a certain threshold)
- People whose heart muscle disease is caused by a genetic reason other than a PKP2 gene mutation
- People who have previously taken part in a gene therapy or gene editing study
- People who have severe dysfunction of the right side of the heart
- People who have the most severe level of heart failure symptoms (classified as NYHA Class IV, meaning symptoms occur even at rest)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Barry Greenberg, MD, University of California, San Diego
Phone: 646-627-0033
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Evaluation of safety associated with RP-A601
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.